prelum 6 mg apvalkotās tabletes
sanoswiss uab, lithuania - lacidipīns - apvalkotā tablete - 6 mg
prelum 4 mg apvalkotās tabletes
sanoswiss uab, lithuania - lacidipīns - apvalkotā tablete - 4 mg
prelum 2 mg apvalkotās tabletes
rivopharm ltd., ireland - lacidipīns - apvalkotā tablete - 2 mg
caduet 5 mg/10 mg apvalkotās tabletes
upjohn eesv, netherlands - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/10 mg
caduet 10 mg/10 mg apvalkotās tabletes
pfizer europe ma eeig, united kingdom - amlodipinum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg
caduet 5 mg/10 mg apvalkotās tabletes
pfizer europe ma eeig, united kingdom - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/10 mg
caduet 10 mg/10 mg apvalkotās tabletes
upjohn eesv, netherlands - amlodipinum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg
dapagliflozin viatris
viatris limited - dapagliflozīns - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
regiocit šķīdums hemofiltrācijai
baxter holding b.v., netherlands - natrii citras, natrii chloridum - Šķīdums hemofiltrācijai